Incretin and metabolic research: semaglutide, tirzepatide, retatrutide and how the receptor pharmacology compares.
22 articles
Weight Loss & GLP-1
The European research compound market in 2025: regulatory framework, supply chain structure, quality standards across compound categories, and what researchers need to know about sourcing peptides, GLP-1 agonists, and injectable androgens from EU-based suppliers.
5 min read
Weight Loss & GLP-1
The top 10 most-researched peptides of 2025 ranked by published study volume, mechanistic depth, and research versatility. Covering BPC-157, TB-500, semaglutide, ipamorelin, SS-31, retatrutide, PT-141, CJC-1295, tirzepatide, and NAD+ precursor peptides with their current research status.
6 min read
Weight Loss & GLP-1
GLP-1 receptor agonist research is evolving rapidly beyond injectable semaglutide: oral formulations, triple agonists (GLP-1/GIP/glucagon), CNS-targeted analogs, and organ-protective applications. Research guide to the next-generation GLP-1 pipeline and the mechanistic frontiers being explored in 2025–2026.
6 min read
Weight Loss & GLP-1
The history of research compounds spans from the 1930s isolation of testosterone to modern synthetic peptides and GLP-1 agonists. A chronological science history of how anabolic steroids, growth hormone peptides, and metabolic research compounds were discovered, synthesized, and studied over 90 years.
7 min read
Weight Loss & GLP-1
A comprehensive guide to sourcing research peptides in Europe — what quality standards to require, how EU supply chains differ from US suppliers, EU regulatory context, and why independent COA testing is the non-negotiable baseline for legitimate European research peptide supply.
4 min read
Weight Loss & GLP-1
Semaglutide, retatrutide, and tirzepatide represent three generations of incretin-based therapy with distinct receptor targets. Research comparison of mechanisms, clinical trial weight loss data, receptor pharmacology, and research applications for each compound class.
4 min read
Weight Loss & GLP-1
GLP-1 receptor agonists are among the most studied compounds in metabolic biology research. Protocol design guide covering GLP-1/GIP/GCG receptor mechanisms, compound selection for obesity and glucose homeostasis research, and in vitro and in vivo endpoint design.
4 min read
Weight Loss & GLP-1
Understanding fair market pricing for research peptides, SARMs, anabolic steroids, and GLP-1 agonists in the European market. What drives price differences, what pricing signals quality vs. cost-cutting, and how to evaluate value for research budgets.
4 min read
Weight Loss & GLP-1
Semaglutide for laboratory research in Europe requires high purity HPLC-MS verified compound, proper cold-chain logistics, and verifiable third-party testing. Research procurement guide for semaglutide in the European market.
4 min read
Weight Loss & GLP-1
Improper storage of research compounds — peptides, steroids, SARMs, and GLP-1 agonists — causes degradation that invalidates experimental results. Complete storage guide covering temperature requirements, light sensitivity, humidity, and practical lab storage solutions.
4 min read
Weight Loss & GLP-1
How to source research-grade retatrutide in Europe. What to look for in a verified supplier — HPLC certificates, EU warehouse stock, ZPHC-quality vials and pens. Updated 2025.
7 min read
Weight Loss & GLP-1
Complete guide to retatrutide research dosing protocols — Phase 2 escalation schedules, reconstitution calculations for vials, and pen format instructions. Based on published clinical trial data.
7 min read
Weight Loss & GLP-1
Head-to-head comparison of retatrutide (triple GIP/GLP-1/glucagon agonist) vs tirzepatide (dual GIP/GLP-1). Phase 2 and Phase 3 data, mechanism differences, and what the research says about each.
9 min read
Weight Loss & GLP-1
A mechanistically rational weight loss research stack combining semaglutide, retatrutide, HGH Fragment 176-191, and MOTS-c — covering appetite suppression, thermogenesis, lipolysis, and metabolic enhancement in one protocol.
7 min read
Weight Loss & GLP-1
T3 (triiodothyronine, liothyronine) is the active thyroid hormone that drives basal metabolic rate. Research overview covering thyroid hormone receptor signaling, thermogenesis, metabolic effects, and protocols for metabolic research.
8 min read
Weight Loss & GLP-1
A mechanistic deep-dive into triple GIP/GLP-1/glucagon receptor co-agonism — why each receptor contributes distinct weight loss and metabolic effects, and why their combination is synergistic rather than merely additive.
8 min read
Weight Loss & GLP-1
Deep analysis of the NEJM Phase 2 retatrutide trial (Jastreboff 2023) — 24% weight loss at 48 weeks, dose-response data, glycemic outcomes, and what the results mean for obesity pharmacotherapy research.
7 min read
Weight Loss & GLP-1
How semaglutide controls blood glucose through GLP-1R-mediated insulin secretion, glucagon suppression, and gastric emptying slowing — with clinical trial HbA1c data and mechanistic analysis.
8 min read
Weight Loss & GLP-1
A comprehensive overview of the GLP-1 receptor agonist drug class — mechanism, clinical evolution from exenatide to semaglutide, and the expanding role of GLP-1R signaling in metabolic disease, cardiovascular health, and neuroscience.
8 min read
Weight Loss & GLP-1
A research-focused analysis of semaglutide's adverse effect profile — nausea, thyroid C-cell findings, pancreatitis signal, and rare events — with mechanistic explanations from GLP-1R pharmacology.
8 min read
Weight Loss & GLP-1
Semaglutide requires gradual dose escalation to minimize GI side effects. This guide covers escalation schedules used in clinical trials and their rodent-equivalent adaptations for research protocols.
6 min read
Weight Loss & GLP-1
Comparing semaglutide administration via pharmaceutical auto-injector pen vs. research-grade vial reconstitution — accuracy, flexibility, storage, and which is appropriate for laboratory research protocols.
6 min read
Resellers, laboratories and publishers: apply for partner pricing, volume terms and a dedicated representative.
Research use only. All products are sold strictly for in-vitro and laboratory research. Not for human consumption, veterinary use, diagnosis, treatment or prevention of any disease. Products sold by JuicedPharma are not medicines. By ordering you confirm you are a qualified person buying for research in compliance with applicable regulations. Full disclaimer